We are international

Sydney 2005:
Mechanisms of Oncogenesis in Waldenstrom's Macroglobulinemia
By Linda Pilarski, MD
Dr. Linda Pilarski opened the session with an overview of WM, which accounts for 2% of hematologic malignancies and has a median survival of 5 years. WM is characterized by lymphoplasmacytic lymphoma and IgM monoclonal gammopathy. Malignant WM cells express a B cell marker (CD20), sIgM, and sIgD. As discussed in Plenary Session 6, hyaloronan synthetase 1 (HAS1) synthesizes hyaluronan (HA), an extracellular matrix protein that is involved in cell signaling and in malignant progression. In WM, HAS1 is overexpressed and undergoes aberrant genetic splicing. She and her associates researched the effect of this abnormal splicing and speculate that abnormalities and mutations in HAS1 may play an important role in WM oncogenesis.

Back to session summary

 related articles